FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Besides Wall Street's top -and-bottom-line estimates for Regeneron (REGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

The top 20 biopharmas demonstrated a strong start to 2025, despite ongoing uncertainty surrounding Trump’s tariffs.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Sanofi (SNY) stock and Roche (RHHBY) stock trade flat after the duo reaffirmed 2025 forecasts despite strong Q1 results. Read ...

In this Healio Video Perspective from the Congress on Controversies in Ophthalmology, Lloyd Clark, MD, discusses sustained ...

Pelthos Therapeutics, a Durham-based wholly owned subsidiary of Ligand Pharmaceuticals (Nasdaq: LGND), is combining with ...

The Swiss pharma giant made one of the most significant financial promises to bolster its domestic manufacturing capabilities as the Trump administration weighs levying tariffs on drugmakers.

Learn more about whether LeMaitre Vascular, Inc. or Lantheus Holdings, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Sanofi SNY reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks ...

This was the stock's third consecutive day of gains.